These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38623974)

  • 1. Preclinical Pharmacokinetics and Pharmacology Study of RC98: A Programmed Cell Death Ligand 1 Monoclonal Antibody in Cynomolgus Monkeys.
    Wang L; Li Q; Deng C; Liu Z; Wang F; Li S; Dong L; Jiang J
    Curr Pharm Des; 2024; 30(16):1240-1246. PubMed ID: 38623974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical evaluation of the efficacy, pharmacokinetics and immunogenicity of JS-001, a programmed cell death protein-1 (PD-1) monoclonal antibody.
    Fu J; Wang F; Dong LH; Zhang J; Deng CL; Wang XL; Xie XY; Zhang J; Deng RX; Zhang LB; Wu H; Feng H; Chen B; Song HF
    Acta Pharmacol Sin; 2017 May; 38(5):710-718. PubMed ID: 28317872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Translate Pharmacokinetics of PD-1/PD-L1 Monoclonal Antibodies from Cynomolgus Monkey to Human: Comparison of Different Approaches.
    Chen W; Wang L; Ruan Z; Lou H; Jiang B
    J Pharm Sci; 2024 Sep; 113(9):2915-2921. PubMed ID: 38986869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biophysical and Immunological Characterization and
    Hutchins B; Starling GC; McCoy MA; Herzyk D; Poulet FM; Dulos J; Liu L; Kang SP; Fayadat-Dilman L; Hsieh M; Andrews CL; Ayanoglu G; Cullen C; Malefyt RW; Kastelein RA; Saux SL; Lee J; Li S; Malashock D; Sadekova S; Soder G; van Eenennaam H; Willingham A; Yu Y; Streuli M; Carven GJ; van Elsas A
    Mol Cancer Ther; 2020 Jun; 19(6):1298-1307. PubMed ID: 32229606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CS1003, a novel human and mouse cross-reactive PD-1 monoclonal antibody for cancer therapy.
    Li F; Li J; Yin K; Zhang J; Li ZH; Lu L; Bao YW; Qin Z; Zheng Y; Yang BT; Li J; Wang X
    Acta Pharmacol Sin; 2021 Jan; 42(1):142-148. PubMed ID: 32467569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A fully human monoclonal antibody targeting PD-L1 with potent anti-tumor activity.
    Luan Y; Chai D; Peng J; Ma S; Wang M; Ma H; Li X; Fu S; Pan X; Wang X; Qin S; Xu T
    Int Immunopharmacol; 2016 Feb; 31():248-56. PubMed ID: 26773772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fully human anti-BAFF inhibitory monoclonal antibody tabalumab does not adversely affect T-dependent antibody responses in cynomolgus monkey (Macaca fasicularis): A summary of three pre-clinical immunotoxicology evaluations.
    Komocsar WJ; Blackbourne JL; Halstead CA; Winstead CJ; Wierda D
    J Immunotoxicol; 2016; 13(1):7-19. PubMed ID: 25585959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical and translational pharmacology of afucosylated anti-CCR8 antibody for depletion of tumour-infiltrating regulatory T cells.
    Gampa G; Spinosa P; Getz J; Zhong Y; Halpern W; Esen E; Davies J; Chou C; Kwong M; Wang Y; Arenzana TL; Shivva V; Huseni M; Hsieh R; Schartner J; Koerber JT; Rutz S; Hosseini I
    Br J Pharmacol; 2024 Jul; 181(13):2033-2052. PubMed ID: 38486310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An optimized protocol for the in vitro generation and functional analysis of human PD1/PD-L1 signal.
    Khedri M; Abnous K; Rafatpanah H; Ramezani M
    J Recept Signal Transduct Res; 2018 Feb; 38(1):31-36. PubMed ID: 29252078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Poor outcome with anti-programmed death-ligand 1 (PD-L1) antibody due to poor pharmacokinetic properties in PD-1/PD-L1 blockade-sensitive mouse models.
    Kurino T; Matsuda R; Terui A; Suzuki H; Kokubo T; Uehara T; Arano Y; Hisaka A; Hatakeyama H
    J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32041818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effects of anti-PD-L1 monoclonal antibody and EGFR-TKI on the expression of PD-L1 and function of T lymphocytes in EGFR-mutated lung cancer cells].
    She Y; Pan X; Xing YF; Zhou T; Zhang ZL; Shi MH; Chen YJ
    Zhonghua Zhong Liu Za Zhi; 2016 Dec; 38(12):886-892. PubMed ID: 27998463
    [No Abstract]   [Full Text] [Related]  

  • 12. Development of an in vitro assay for screening programmed death receptor-1/programmed cell death ligand 1 monoclonal antibody therapy in dogs.
    Mizuno T; Kato M; Tsukui T; Igase M
    Vet Immunol Immunopathol; 2024 Aug; 274():110792. PubMed ID: 38878679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Programmed Cell Death-1: Programmed Cell Death-Ligand 1 Interaction Protects Human Cardiomyocytes Against T-Cell Mediated Inflammation and Apoptosis Response In Vitro.
    Tay WT; Fang YH; Beh ST; Liu YW; Hsu LW; Yen CJ; Liu PY
    Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32244307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Fc-muted bispecific antibody targeting PD-L1 and 4-1BB induces antitumor immune activity in colorectal cancer without systemic toxicity.
    Cheng LS; Zhu M; Gao Y; Liu WT; Yin W; Zhou P; Zhu Z; Niu L; Zeng X; Zhang D; Fang Q; Wang F; Zhao Q; Zhang Y; Shen G
    Cell Mol Biol Lett; 2023 May; 28(1):47. PubMed ID: 37259060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Programmed death receptor-1/programmed death receptor ligand-1 blockade after transient lymphodepletion to treat myeloma.
    Kearl TJ; Jing W; Gershan JA; Johnson BD
    J Immunol; 2013 Jun; 190(11):5620-8. PubMed ID: 23616570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor.
    Deng R; Bumbaca D; Pastuskovas CV; Boswell CA; West D; Cowan KJ; Chiu H; McBride J; Johnson C; Xin Y; Koeppen H; Leabman M; Iyer S
    MAbs; 2016; 8(3):593-603. PubMed ID: 26918260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the programmed cell death 1: programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with sepsis.
    Chang K; Svabek C; Vazquez-Guillamet C; Sato B; Rasche D; Wilson S; Robbins P; Ulbrandt N; Suzich J; Green J; Patera AC; Blair W; Krishnan S; Hotchkiss R
    Crit Care; 2014 Jan; 18(1):R3. PubMed ID: 24387680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of pharmacodynamic activity, pharmacokinetics, and anti-product antibody responses to anti-IL-21R antibody therapeutics following IV administration to cynomolgus monkeys.
    Vugmeyster Y; Allen S; Szklut P; Bree A; Ryan M; Ma M; Spaulding V; Young D; Guay H; Bloom L; Leach MW; O'Toole M; Adkins K
    J Transl Med; 2010 Apr; 8():41. PubMed ID: 20420683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CCX559 is a potent, orally-administered small molecule PD-L1 inhibitor that induces anti-tumor immunity.
    Sullivan KMC; Vilalta M; Ertl LS; Wang Y; Dunlap C; Ebsworth K; Zhao BN; Li S; Zeng Y; Miao Z; Fan P; Mali V; Lange C; McMurtrie D; Yang J; Lui R; Scamp R; Chhina V; Kumamoto A; Yau S; Dang T; Easterday A; Liu S; Miao S; Charo I; Schall TJ; Zhang P
    PLoS One; 2023; 18(6):e0286724. PubMed ID: 37285333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frontline Science: Anti-PD-L1 protects against infection with common bacterial pathogens after burn injury.
    Patil NK; Luan L; Bohannon JK; Hernandez A; Guo Y; Sherwood ER
    J Leukoc Biol; 2018 Jan; 103(1):23-33. PubMed ID: 29345058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.